molmed

Investors

Notice of ordinary meeting April 12, 2018

Notice of ordinary meeting April 12, 2018 ▾

Investors

MolMed: Board of Directors approved Full Year 2017 Results

MolMed: Board of Directors approved Full Year 2017 Results ▾

Investors

Corporate Presentation FY2017

Corporate Presentation FY2017 ▾

Last presentation

DOWNLOAD

Investors

MolMed and Miltenyi Biotec: EMA approves the utilization of CliniMACS Prodigy® in the commercial manufacturing of Zalmoxis®

MolMed and Miltenyi Biotec: EMA approves the utilization of CliniMACS Prodigy® in the commercial manufacturing of Zalmoxis® ▾

Investors

MolMed: AIFA Determina on reimbursement regime and market price for the proprietary cell therapy Zalmoxis® published on the Official Gazette

MolMed: AIFA Determina on reimbursement regime and market price for the proprietary cell therapy Zalmoxis® published on the Official Gazette ▾

Investors

MolMed: Dompé exercises the option right to undertake the market access and commercialization activities for Zalmoxis® in Switzerland, Turkey and Australia.

MolMed: Dompé exercises the option right to undertake the market access and commercialization activities for Zalmoxis® in Switzerland, Turkey and Australia. ▾

Investors

Financial calendar 2018

Financial calendar 2018 ▾

News & Events

Stay update

SECOND EDITION OF INVESTOR DAY IN FRANKFURT ▾

SECOND EDITION OF INVESTOR DAY IN FRANKFURT

News & Events

Stay update

Cell&Gene Therapy world Miami (USA) ▾

Cell&Gene Therapy world Miami (USA)

Location: Hyatt Regency, Miami USA

MolMed at this event: Luca Alberici Chief Business Officer at MolMed: How are CMO consolidation trends and business/collaboration models set to evolve (eg. the 'one-stop shop')?

Investors

Zalmoxis®: price & reimbursement dossier filed in Germany, where the product can be prescribed and reimbursed as of January 15th

Zalmoxis®: price & reimbursement dossier filed in Germany, where the product can be prescribed and reimbursed as of January 15th ▾

Subscribe to

Subscribe to press releases

Dear Users, we would like to inform you that, as of 30 September, AGC Biologics S.p.A. (formerly MolMed S.p.A.) is no longer listed on the Milan Stock Exchange and has become part of the AGC Biologics Group. For any information on the company and the group, you are kindly invited to consult the websitewww.agcbio.com.
The contents present on this portal (www.molmed.com) are updated until the date of September 30, 2020 and will be available for the time frame foreseen by applicable regulations.
In addition, the "work with us" section is still active, while the contact details are no longer accessible.